Your browser doesn't support javascript.
loading
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
Grande, Enrique; Teulé, Alex; Alonso-Gordoa, Teresa; Jiménez-Fonseca, Paula; Benavent, Marta; Capdevila, Jaume; Custodio, Ana; Vera, Ruth; Munarriz, Javier; La Casta, Adelaida; Díez, Juan José; Gajate, Pablo; Molina-Cerrillo, Javier; Matos, Ignacio; Cristóbal, Eva María; Ruffinelli, José C; Palacios, José; García-Carbonero, Rocío.
Afiliación
  • Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Teulé A; Department of Medical Oncology, Catalan Institute of Oncology (Hospital Duran i Reynals), L'Hospitalet, Barcelona, Spain.
  • Alonso-Gordoa T; Department of Medical Oncology, University Hospital Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain.
  • Jiménez-Fonseca P; Department of Medical Oncology, University Hospital Central de Asturias, Oviedo, Spain.
  • Benavent M; Department of Medical Oncology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain.
  • Capdevila J; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain.
  • Custodio A; Department of Medical Oncology, University Hospital La Paz, Centro de Investigación Biomédica en Red Cáncer CB16/12/00398, Madrid, Spain.
  • Vera R; Department of Medical Oncology, Complejo Hospitalario de Navarra, IdisNA, Pamplona, Spain.
  • Munarriz J; Department of Medical Oncology, University Hospital General de Castellon, Castellon, Spain.
  • La Casta A; Department of Medical Oncology, University Hospital Donostia, San Sebastián, Spain.
  • Díez JJ; Department of Endocrinology, University Hospital Puerta de Hierro Majadahonda, Department of Medicine, Faculty of Medicine, Universidad Autónoma, Madrid, Spain.
  • Gajate P; Department of Medical Oncology, University Hospital Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain.
  • Molina-Cerrillo J; Department of Medical Oncology, University Hospital Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain.
  • Matos I; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain.
  • Cristóbal EM; Department of Pathology, University Hospital Ramón y Cajal IRYCIS, CIBERONC, Madrid, Spain.
  • Ruffinelli JC; Department of Medical Oncology, Catalan Institute of Oncology (Hospital Duran i Reynals), L'Hospitalet, Barcelona, Spain.
  • Palacios J; Department of Pathology, University Hospital Ramón y Cajal, Departament of Medicine and Medical Specialties, Faculty of Medicine, University of Alcalá, IRYCIS, CIBERONC, Madrid, Spain.
  • García-Carbonero R; Department of Medical Oncology, University Hospital 12 de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain.
Oncologist ; 25(9): 745-e1265, 2020 09.
Article en En | MEDLINE | ID: mdl-32045050
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumores Neuroendocrinos Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumores Neuroendocrinos Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido